Literature DB >> 10493949

Prognostic significance of polo-like kinase expression in esophageal carcinoma.

Y Tokumitsu1, M Mori, S Tanaka, K Akazawa, S Nakano, Y Niho.   

Abstract

PLK (polo-like kinase), which belongs to a family of serine/threonine kinases and represents the human counterpart of structurally related protein kinases, polo of Drosophila melanogaster and CDC5 of Saccharomyces cerevisiae, may be implicated in spindle formation and chromosome segregation during mitosis. There are, however, few reports on the significance of PLK gene expression in human carcinomas. In order to evaluate its clinical significance, we examined the expression of the PLK mRNA in 49 esophageal and 75 gastric carcinomas, using reverse transcription-polymerase chain reaction analysis. In esophageal carcinomas, PLK overexpression was detected in 47 carcinomas (97%) when compared to the corresponding normal tissues. It is noteworthy that the patients with high-grade PLK overexpression represented a significantly poorer prognosis group than those with low-grade PLK overexpression (3-year survival rate: 54.9% vs 24.8%, p<0.05). A multivariate analysis demonstrated that the PLK mRNA expression status was an independent prognostic factor for patients with esophageal carcinoma. On the other hand, 55 gastric carcinomas (73%) were revealed to overexpress PLK mRNA, but the expression status showed no correlation with prognosis. This study demonstrated that the PLK overexpression was frequently observed in esophageal and gastric carcinomas, and appeared to be an independent prognostic factor for patients with esophageal carcinoma.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10493949     DOI: 10.3892/ijo.15.4.687

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  39 in total

1.  Polo-like kinase 1 regulates cell proliferation and is targeted by miR-593* in esophageal cancer.

Authors:  Tetsuo Ito; Fumiaki Sato; Takatsugu Kan; Yulan Cheng; Stefan David; Rachana Agarwal; Bogdan C Paun; Zhe Jin; Alexandru V Olaru; James P Hamilton; Florin M Selaru; Jian Yang; Nobutoshi Matsumura; Kazuharu Shimizu; John M Abraham; Yutaka Shimada; Yuriko Mori; Stephen J Meltzer
Journal:  Int J Cancer       Date:  2011-03-11       Impact factor: 7.396

2.  Overexpression of Plk1 promotes malignant progress in human esophageal squamous cell carcinoma.

Authors:  Chunling Zhao; Lei Gong; Wentong Li; Limei Chen
Journal:  J Cancer Res Clin Oncol       Date:  2010-01       Impact factor: 4.553

Review 3.  Cdk1, Plks, Auroras, and Neks: the mitotic bodyguards.

Authors:  Patrick Salaun; Yoann Rannou; Claude Prigent
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

Review 4.  Polo-like kinase 1, on the rise from cell cycle regulation to prostate cancer development.

Authors:  Jijing Luo; Xiaoqi Liu
Journal:  Protein Cell       Date:  2012-03-23       Impact factor: 14.870

5.  Polo-like kinase isoforms in breast cancer: expression patterns and prognostic implications.

Authors:  Wilko Weichert; Glen Kristiansen; Klaus-Jürgen Winzer; Mathias Schmidt; Volker Gekeler; Aurelia Noske; Berit-Maria Müller; Silvia Niesporek; Manfred Dietel; Carsten Denkert
Journal:  Virchows Arch       Date:  2005-03-23       Impact factor: 4.064

6.  Targeting subcellular localization through the polo-box domain: non-ATP competitive inhibitors recapitulate a PLK1 phenotype.

Authors:  Campbell McInnes; Kara Estes; Merissa Baxter; Zhengguan Yang; Doaa Boshra Farag; Paul Johnston; John S Lazo; Jianjun Wang; Michael D Wyatt
Journal:  Mol Cancer Ther       Date:  2012-07-30       Impact factor: 6.261

Review 7.  Mitotic chromosomal instability and cancer: mouse modelling of the human disease.

Authors:  Juan-Manuel Schvartzman; Rocio Sotillo; Robert Benezra
Journal:  Nat Rev Cancer       Date:  2010-02       Impact factor: 60.716

Review 8.  Cross Talk between Wnt/β-Catenin and CIP2A/Plk1 Signaling in Prostate Cancer: Promising Therapeutic Implications.

Authors:  Ion Cristóbal; Federico Rojo; Juan Madoz-Gúrpide; Jesús García-Foncillas
Journal:  Mol Cell Biol       Date:  2016-05-31       Impact factor: 4.272

9.  Polo-like kinase 1 is essential for early embryonic development and tumor suppression.

Authors:  Lin-Yu Lu; Jamie L Wood; Katherine Minter-Dykhouse; Lin Ye; Thomas L Saunders; Xiaochun Yu; Junjie Chen
Journal:  Mol Cell Biol       Date:  2008-09-15       Impact factor: 4.272

10.  Elevated levels of the polo kinase Cdc5 override the Mec1/ATR checkpoint in budding yeast by acting at different steps of the signaling pathway.

Authors:  Roberto Antonio Donnianni; Matteo Ferrari; Federico Lazzaro; Michela Clerici; Benjamin Tamilselvan Nachimuthu; Paolo Plevani; Marco Muzi-Falconi; Achille Pellicioli
Journal:  PLoS Genet       Date:  2010-01-22       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.